Tennis woman standing with feet firmly planted

HAEGARDA reduced hae attacks by 95%*

Primary endpointOverall reduction in HAE attacks per month relative to placebo

Tennis woman standing with feet firmly planted

Median Number of HAE Attacks/Month

Chart of median number of HAE attacks/month while on HAEGARDA vs placebo Chart of median number of HAE attacks/month while on HAEGARDA vs placebo
95% reduction in HAE attacks with HAEGARDA 60 IU/kg vs placebo (median)

Study Design A 32-week crossover study with patients ≥12 years of age with symptomatic type 1 or 2 HAE (N=90).1

The WAO Guideline for the Management of HAE states that patients should have HAE rescue medication available at all times2

*Median reduction in number of attacks in patients receiving 60 IU/kg of HAEGARDA vs placebo.

Taking haegarda reduced the use of rescue medication by >99%†1

Secondary endpoint Number of uses of rescue medication per month relative to placebo

99% less rescue medication with HAEGARDA 60 IU/kg vs placebo (median)
  • The WAO Guideline for the Management of HAE states that patients should have HAE rescue medication available at all times2

Secondary endpoint High rate of response1

  • 90% of patients experienced ≥50% reduction in attacks relative to placebo

Median reduction in rescue medication use in patients receiving 60 IU/kg of HAEGARDA vs placebo.

In a long-term study following patients over 1.5 years, HAEGARDA reduced the HAE attack rate to 1 per year‡4 1.0 attack per year

‡Median attack rate in patients followed over an average of 1.5 years.

You are now leaving the current website.